{"nctId":"NCT00041717","briefTitle":"Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury","startDateStruct":{"date":"2002-07"},"conditions":["Spinal Cord Injury","Muscle Spasticity"],"count":213,"armGroups":[{"label":"fampridine-SR 50mg/day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fampridine-SR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Fampridine-SR","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Incomplete traumatic Spinal Cord Injury (at least 18 months prior and stable for 6 months)\n* Moderate to severe lower-limb spasticity\n* Able to give informed consent and willing to comply with protocol\n\nExclusion Criteria:\n\n* Pregnancy\n* History of seizures\n* Existing or history of frequent Urinary Tract Infections\n* History of drug or alcohol abuse\n* Allergy to pyridine-containing substances\n* Received a botox injection 4 months prior to study\n* Received an investigational drug within 30 days\n* Previously treated with 4-aminopyridine (4-AP)\n* Not on stable medication dosing in 3 weeks prior to study\n* Abnormal ECG or laboratory value at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity","description":"The Ashworth Score is the average rating (based on a scale of 1 to 5) of four lower extremity muscle groups; left and right knee flexors and extensors (hamstrings and quadriceps muscles). A higher Ashworth Score indicates a greater degree of abnormal muscle tone (spasticity) and a negative change in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.039"},{"groupId":"OG001","value":"-0.15","spread":"0.042"}]}]}]},{"type":"PRIMARY","title":"Double-blind Change From Baseline in Subject's Global Impression (SGI) of Treatment","description":"This questionnaire asked the patient to evaluate the effects of investigational drug on his/her quality of life during the preceding week using a 7-point scale (from 1=terrible to 7=delighted). A positive change score in SGI indicates improved outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.08"},{"groupId":"OG001","value":"-0.1","spread":"0.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":114},"commonTop":["Urinary tract infection","Hypertonia","Pain","Accidental injury","Constipation"]}}}